Phase 3 – Page 4 – Discover Pharma

Welcome to Discover Pharma! Today is : September 22, 2026

Phase 3

Clinical & Regulatory,Therapeutic Areas
UCB reports positive phase 3 Gemz results as fenfluramine cuts seizure frequency in CDKL5 deficiency disorder
UCB has reported positive findings from the Gemz phase 3 [...]

May 5, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas
GSK’s depemokimab backed by Phase 3 data ahead of FDA decision in asthma and sinusitis
Phase 3 data for GSK’s depemokimab appear to support the [...]

May 5, 2026
Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
InflaRx targets key data readouts for INF904 in skin conditions
InflaRx has reported its Q2 2025 results and provided updates [...]

May 5, 2026
Biotech & Pharma Business,Drug Discovery & Development,Opinion & Events
Could a psychedelic transform depression care? Cybin CEO on scaling CYB003 with Osmind deal
Cybin’s lead psychedelic-based candidate CYB003, designed as an adjunctive treatment [...]

May 5, 2026
Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain
ITM secures $262.5M financing from Blue Owl to drive US launch of radiopharmaceutical for neuroendocrine tumors
Landmark debt deal enables commercial readiness for ITM-11, supports pipeline [...]

May 5, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK